P17-22. Impact of rare adenovirus seroprevalence on HIV-1 acquisition in the Step study

Lori F. Maxfield(Beth Israel Deaconess Medical Center), Dan H. Barouch(Beth Israel Deaconess Medical Center), AM Riggs(Beth Israel Deaconess Medical Center), Rebecca Dilan(Beth Israel Deaconess Medical Center), MJ McElrath(Infectious Disease Research Institute), Anne Laporte(Institut Pasteur), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), SL King(Beth Israel Deaconess Medical Center), Jaap Goudsmit(Leiden University)
Retrovirology
October 1, 2009
10.1186/1742-4690-6-s3-p304
Cited by 0

Related Papers

An immunogenic personal neoantigen vaccine for patients with melanoma
|Nature|2017|3k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Potently neutralizing and protective human antibodies against SARS-CoV-2
|Nature|2020|1.2k
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
|Science|2020|1.1k
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
|Nature|2020|904